The following drugs will require authorization in 2025:
| Drug Name | Generic | Code | Medicare Effective Date | Commercial Effective Date |
|---|---|---|---|---|
| Alyglo | immune globulin (alygo) | J1552 | 1/1/2025 | 1/1/2025 |
| Axtle | pemetrexed (avyxa) | J9292 | 1/1/2025 | 1/1/2025 |
| Bizengri | Zenocutuzumab-zbco | J3590 | No PA Required | 2/1/2025 |
| Bkemv | eculizumab-aeeb (bkemv) | Q5139 | 1/1/2025 | 1/1/2025 |
| Docivyx | docetaxel | J9172 | 2/1/2025 | 2/1/2025 |
| Fulphila | biosimilar pegfilgrastim | Q5108 | 1/1/2025 | 1/1/2025 |
| Hercessi | trastuzumab-strf (hercessi) | Q5146 | 1/1/2025 | 1/1/2025 |
| Nypozi | filgrastim-txid (nypozi), biosimilar | C9173 | 1/1/2025 | 1/1/2025 |
| Ocrevus Zunovo | ocrelizumab and hyaluronidase | J3590 | No PA Required | 1/1/2025 |
| Pemrydi RTU | Pemetrexed Disodium IV Soln | J9324 | 2/1/2025 | 2/1/2025 |
| Pyzchiva | ustekinumab-ttwe (pyzchiva) | Q9997 | 1/1/2025 | 1/1/2025 |
| Romiplostim | romiplostim | J2802 | 1/1/2025 | 1/1/2025 |
| Tecelra | afamistresgene autoleucel | J3590 | No PA Required | 1/1/2025 |
| Tecentriq Hybreza | atezolizumab and hyaluronidase | J3590 | No PA Required | 1/1/2025 |
| Ziihera | Zanidatamab-HRII | J3590 | No PA Required | 1/1/2025 |